Substituted [1,2,4]triazolo[1,5-a]pyrazines as spleen tyrosine kinase inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,
• wherein:
• R3 is benzodioxolyl, 2H-1,4-benzoxazin-3(4H)-onyl, 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-onyl, pyrazolyl, thiazolyl, pyridinyl, pyrazinyl, indolyl, isoindolyl, indazolyl, or benzothiazolyl, wherein the benzodioxolyl, 2H-1,4-benzoxazin-3(4H)-onyl, 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-onyl, pyrazolyl, thiazolyl, pyridinyl, pyrazinyl, indolyl, isoindolyl, indazolyl, or benzothiazolyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)NHR5, C(O)OH, NH2, OC1-6 alkyl, and C3-8 cycloalkyl;
• R4 is benzodioxolyl, phenyl, or pyridinyl;
• wherein the benzodioxolyl, phenyl, or pyridinyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of halo, C1-6 alkyl, OC1-6 alkyl, piperazinyl, 4-hydroxy-4-methylpiperazin-1-yl, C3-8 cycloalkoxy, morpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, and 2-oxa-6-azaspiro[3.4]octan-6-yl;
• wherein each C1-6 alkyl and OC1-6 alkyl substituent is optionally and independently substituted with one, two, or three independently selected halo substituents;
• wherein each piperazinyl substituent is optionally and independently substituted with one or two substituents independently selected from the group consisting of C1-6 alkyl, CF3, CH2CF3, CH(OH)CH3, CH2CH2OH, CH(OCH3)CH3, CH2CH2OCH3, S(O)2CH3, S(O)2CH2CH3, C3-8 cycloalkyl, and C2-6 cycloalkoxy;
• and
• wherein each 2,5-diazabicyclo[2.2.1]heptan-2-yl substituent is optionally and independently substituted with one or two substituents independently selected from the group consisting of C1-6 alkyl and C2-6 cycloalkoxy;
• and
• each R5 is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or OC(O)phenyl.